<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Omega</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id>
    <journal-id journal-id-type="publisher-id">ao</journal-id>
    <journal-id journal-id-type="coden">acsodf</journal-id>
    <journal-title-group>
      <journal-title>ACS Omega</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2470-1343</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10034828</article-id>
    <article-id pub-id-type="doi">10.1021/acsomega.2c08147</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SCARdock: A Web
Server and Manually Curated Resource
for Discovering Covalent Ligands</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Song</surname>
          <given-names>Qi</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="notes3" ref-type="notes">#</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Zeng</surname>
          <given-names>Lingyu</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="notes3" ref-type="notes">#</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Zheng</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5182-7241</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Sen</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Cooperative
Innovation Center of Industrial Fermentation (Ministry of Education
&amp; Hubei Province) &amp; Key Laboratory of Fermentation Engineering
(Ministry of Education), <institution>Hubei University
of Technology</institution>, Wuhan 430068, <country>China</country></aff>
      <aff id="aff2"><label>‡</label>Hubei
Key Laboratory of Industrial Microbiology &amp; National “111”
Center for Cellular Regulation and Molecular Pharmaceutics, <institution>Hubei University of Technology</institution>, Wuhan 430068, <country>China</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>senliu.ctgu@gmail.com</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>06</day>
      <month>03</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>21</day>
      <month>03</month>
      <year>2023</year>
    </pub-date>
    <volume>8</volume>
    <issue>11</issue>
    <fpage>10397</fpage>
    <lpage>10402</lpage>
    <history>
      <date date-type="received">
        <day>23</day>
        <month>12</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>22</day>
        <month>02</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao2c08147_0003" id="ab-tgr1"/>
      </p>
      <p>Background: Covalent
drugs have been intentionally discarded historically
due to the concern of off-target side effects, but the past decade
has seen a fast resurgence of the discovery of covalent drugs. Compared
to noncovalent ligands, covalent ligands might have better biochemical
efficiency, lower patient burden, less dosing frequency, less drug
resistance, and improved target specificity. Results: Previously,
we proposed the steric-clashes alleviating receptor (SCAR) strategy
for screening and repurposing covalent inhibitors. To help the discovery
of covalent ligands targeting protein targets, we have developed a
web server dedicated to providing the SCARdock protocol to general
users. Along with this server, we presented three high-quality data
sets for the discovery of covalent ligands: a manually curated data
set containing 954 high-quality complex structures of covalent ligands
and proteins, a manually curated data set of 68 experimentally confirmed
covalent warheads targeting 11 different residues, and a prefiltered,
classified, and ready-to-use data set of 690,018 entries of purchasable
virtual compounds containing these experimentally verified warheads.
Conclusions: The SCARdock server and the accompanied data sets would
be of great value to the discovery of covalent ligands and are available
freely at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.liugroup.site/scardock/">http://www.liugroup.site/scardock/</uri> or <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scardock.com">https://scardock.com</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>31971150</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Department of Science and Technology, Hubei Provincial People''s Government</institution>
            <institution-id institution-id-type="doi">10.13039/501100010580</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2019CFA069</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Hubei University of Technology</institution>
            <institution-id institution-id-type="doi">10.13039/501100002948</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NA</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ao2c08147</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ao2c08147</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Although
small molecules can bind to protein targets either noncovalently
or covalently, covalent drugs were intentionally avoided historically
due to the concern of toxicity caused by nonspecific modifications
of nontargeted biomolecules.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> However,
since the retrospective study revealed that the covalent mechanism
is indispensable for many well marketed drugs including aspirin and
penicillin,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> the advantages of covalent
drugs have been re-evaluated. It is now recognized that compared to
noncovalent drugs, covalent drugs might have better biochemical efficiency,
lower patient burden, less dosing frequency, less drug resistance,
and sometimes improved target specificity.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> This conceptual change has resulted in a huge boost in the discovery
of covalent drugs in the past decade. Currently, over ten intentionally
designed covalent drugs have been approved for clinical use,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> among which are ibrutinib, a covalent inhibitor
of Bruton’s tyrosine kinase for treating B-cell cancers, and
sotorasib, a covalent inhibitor targeting the once “undruggable”
KRAS for treating nonsmall cell lung cancer. Covalent ligands are
also attracting attentions in the development of PROTACs (proteolysis
targeting chimeras) and protein–protein interaction regulators.<sup><xref ref-type="bibr" rid="ref4">4</xref>−<xref ref-type="bibr" rid="ref6">6</xref></sup></p>
    <p>The computational tools for discovering covalent ligands of
proteins
had also been underdeveloped for a long time. Previously, Abagyan
et al. implemented covalent docking in ICM by converting ligands into
pseudoligands covalently attached to the side chain of residue,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> and Jones et al. developed GOLD with covalent
docking functionality by using link atoms added to both ligand and
receptor.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Nonetheless, covalent docking
was not a focus of these computation-aided drug discovery (CADD) tools.
With the escalating interests in covalent drugs, the number of CADD
software for the virtual screening of covalent ligands has increased
significantly in the past decade. Morris et al. designed AutoDock4
for docking covalent ligands with either a grid-based approach or
an approach using flexible side chains.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Lawandi et al. updated FITTED to consider covalent and noncovalent
docking simultaneously based on an automated identification of the
ligand warhead atoms, and Labarre et al. introduced new features and
data sets implemented in FITTED to broaden the ability of docking
covalent inhibitors and metalloenzymes.<sup><xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup> Ouyang et
al. developed CovalentDock based on Autodock by utilizing a dummy
atom to conceptually link the residue and the ligand.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Warshaviak et al. established CovDock-VS, a virtual screening
version of the Schrodinger’s CovDock<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> for docking covalent ligands.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> London
et al. created DOCKovalent by constraining predefined covalent bonds
from the noncovalent docking program DOCK3.6 for screening electrophilic
molecules.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Scholz et al. developed DOCKTITTE
in the Molecular Operating Environment (MOE) by combining warhead
screening, side chain attachment, pharmacophore-guided docking, and
side-chain cleavage and pose rescoring.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Hoffer et al. presented Covadots, a covalent inhibitor design protocol
by identifying chemical moieties to link noncovalent substructures
with reactive protein residue.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Wei et
al. implemented Cov_FB3D, a covalent inhibitor design protocol based
on AutoDock v 4.2 by combining fragment-based drug design, molecular
mechanism (MM) and quantum mechanical (QM) calculations.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Scarpino et al. proposed the covalent docking
protocol WIDOCK by incorporating ligand reactivity in to AutoDock
v 4.2.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Wu and Huang proposed the covalent
docking protocol HCovDock by balancing the contributions between covalent
and noncovalent interaction.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> Wei et al.
proposed Cov_DOX for covalent docking that achieved a high success
rate of accurate binding structures of protein–ligand complexes.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></p>
    <p>Although there are so many covalent docking
tools now, free web
servers for convenient covalent ligand screening are very limited.
One web server is DOCKovalent (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://covalent.docking.org">http://covalent.docking.org</uri>), but this server only has 12 warheads
targeting limited residues such as Cys, Thr, and Ser. Another Web
server is CovalentDock Cloud,<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> but this server is
outdated and not reachable anymore. One successfully verified strategy
in the design of covalent inhibitors is appending covalently reactive
chemical groups (warheads) to a noncovalent inhibitor. This strategy
supports the theory that the noncovalent binding step positions the
warhead for covalent bonding. Based on this theory, we proposed the
SCARdock protocol, which has been successfully applied in drug screening
and repurposing recently.<sup><xref ref-type="bibr" rid="ref24">24</xref>−<xref ref-type="bibr" rid="ref27">27</xref></sup> To make computational screening of covalent ligands
accessible more easily and widely, we set up a free web server of
SCARdock. Along with this server, we collected and organized three
useful data sets: a manually curated data set containing 954 published
high-quality complex structures of covalent ligands and protein targets,
a manually collected and curated data set of 68 experimentally confirmed
covalent warheads targeting 11 different residues, and a prefiltered,
classified, and ready-to-use data set of 690,018 entries of purchasable
compounds containing these experimentally verified warheads. To our
best knowledge, these data sets might be the most comprehensive and
the largest ones of their kind thus far. Our server and data sets
would be of great value to the discovery of covalent ligands.</p>
  </sec>
  <sec id="sec2">
    <title>Construction
and Content</title>
    <sec id="sec2.1">
      <title>Data Collection and Manual Curation of High-Quality Complexes
of Covalent Ligands and Proteins</title>
      <p>A high-quality data set
of covalent ligand–protein complexes is indispensable for developing,
validating, and evaluating covalent ligand docking protocols. Previously,
we<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> and other groups<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref16">16</xref></sup> used a data set containing 76 protein-inhibitor
complexes for evaluating different computational tools. That data
set was collected ten years ago<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> when
the rational discovery of covalent drugs just started to gain attention.
The past decade has seen fast growth of experimentally determined
complexes of covalent ligands with different protein targets. Hence,
it would be of great value to prepare an updated data set of covalent
ligand–protein complexes to help the rational discovery of
covalent ligands.</p>
      <p>Recently, Scarpino et al.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and Du et al.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> independently
prepared two covalent ligand–protein complex data sets. Combining
the reported data from these two papers and the data set we used previously,
we obtained 390 complex structures. Additionally, we searched the
PDB databank with the keywords “covalent” and “inhibitor”
along with the settings “compatible with PDB format = Y”
and “data collection resolution ≤2.5 Å”.
As of Dec 01, 2021, we obtained 2,006 structures from the PDB databank.
Combining these entries and removing duplications, we finally obtained
2,196 covalent ligand–protein complexes with PDB structures.
To confirm the covalent binding information in these collected structures,
ligand IDs, covalent bonds, and references were retrieved from the
PDB files via the “LINK” and “JRNL” fields.
PDB files without covalent bonds were discarded. At last, all covalent
bonds between ligands and proteins were visually confirmed in Pymol.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> Finally, we obtained 954 covalent ligand–protein
complexes with experimental PDB structures (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A,B, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.2c08147/suppl_file/ao2c08147_si_001.pdf">Table S1</ext-link>). To get these files ready for virtual docking analysis, we kept
one chain only if there were multiple chains in the PDB file and removed
the ligands/atoms (such as waters, ions, and noncovalent ligands)
not belong to the target chain(s) and the covalent ligand. General
molecules such as cofactors and solutes were also discarded (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.2c08147/suppl_file/ao2c08147_si_001.pdf">Table S2</ext-link>). In total, these structures contain
935 ligands, and all ligands were validated via a PDB API (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/ligand-vlidation/PDBID/ligandid">https://www.rcsb.org/ligand-vlidation/PDBID/ligandid</uri>).<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> We also collected the chemical features
and DrugBank features using another PDB API (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/ligand/ligandname">https://www.rcsb.org/ligand/ligandname</uri>).<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> The detailed information is provided
as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.2c08147/suppl_file/ao2c08147_si_001.pdf">Table S1</ext-link>, including PDB IDs, covalent
residues, ligand names, SMILES expressions, molecular weights, reference
Pubmed IDs, etc.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Data collection of covalent ligand–protein complexes
and
experimentally verified covalent warheads. (A) Collection pipeline
of covalent ligand–protein complexes. (B) Statistics of the
collected covalent complexes. (C) A screenshot of the warhead list
on the SCARdock web server. (D) A screenshot of the warhead information
page on the SCARdock web server.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao2c08147_0001" id="gr1" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.2">
      <title>Data Collection and Manual Curation of Experimentally Verified
Covalent Warheads</title>
      <p>During the design of covalent ligands,
the selection of suitable warheads is critical. In our SCARdock protocol,
warheads are used to filter compound libraries so that only ligands
containing suitable warheads are used for docking. A warhead is a
chemically reactive moiety, but its reactivity is also affected by
the environment of the binding pocket of the protein. Meanwhile, the
same warhead might have different reactivities on different molecular
scaffolds. Furthermore, to limit off-target effects, not all chemically
active warheads are suitable to be incorporated in covalent drugs.
Therefore, a data set of valid warheads is highly valuable. To prepare
this data set, we decided to only collect the warheads confirmed by
reliable experimental assays. Therefore, a warhead was collected only
when it was confirmed by at least one of the following types of experimental
evidence: a complex structure, NMR data, and mass spectrometry. All
data were confirmed by checking the original reports. After going
through over 100 papers, we prepared a data set containing 68 unique
warheads targeting 11 different residues (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.2c08147/suppl_file/ao2c08147_si_001.pdf">Table S3</ext-link>). A note is that one warhead could be used to target two
or more residues. Additional information was also collected and reported
for each warhead, including reversibility, targeting residues, leaving
groups, bonding atoms, SMILES expressions, reaction mechanisms, references,
etc. On the SCARdock server, the warheads were classified and ordered
by their targeting residues. Users can easily locate the warhead of
interest by the residues and the serial number of the warhead (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C). Each warhead
has an information page displaying its generic name, leaving group,
end product, reversibility, references, etc. (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>D).</p>
    </sec>
    <sec id="sec2.3">
      <title>Data Collection and Preparation of Compound
Data Set Containing
Experimentally Verified Covalent Warheads</title>
      <p>Virtual screening
compound libraries are indispensable for <italic>in silico</italic> docking. Although some commercial ventures are starting to provide
covalent compound libraries for virtual screening, the warhead numbers
and the targeting residues are very limited. Based on our manually
curated warhead data set, we compiled a screening data set of purchasable
covalent compounds from several representative commercial ventures
(<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Currently,
our data set contains 690,018 compounds targeting 11 different residues,
among which there are 13,976 for Asp, 132,717 for Cys, 3,861 for Glu,
72,983 for His, 28,468 for Lys, 3,856 for Met, 5,312 for Pro, 38,194
for Pyr (pyruvoyl), 258,204 for Ser, 128,040 for Thr, and 4,407 for
Tyr. A note is that if a compound contains more than one warhead or
can target more than one residue, it is recounted upon each match.
For each warhead, the bonding atom was identified and recorded for
distance calculation later in the SCARdock protocol. The 3D conformations
of all molecules were generated with RDKit<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> from SDF files. On the SCARdock web server, the prefiltered compound
data sets are available for download in MOL and PDBQT files. The PDBQT
files are ready for docking with Autodock Vina<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> locally or on the server.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Statistic
Information of the Prepared
Compound Dataset Filtered by Experimentally Verified Covalent Warheads</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center"> </th>
              <th colspan="11" align="center">Targeting
Residue<hr/></th>
            </tr>
            <tr>
              <th style="border:none;" align="center">Source Library</th>
              <th style="border:none;" align="center">Asp</th>
              <th style="border:none;" align="center">Cys</th>
              <th style="border:none;" align="center">Glu</th>
              <th style="border:none;" align="center">His</th>
              <th style="border:none;" align="center">Lys</th>
              <th style="border:none;" align="center">Met</th>
              <th style="border:none;" align="center">Pro</th>
              <th style="border:none;" align="center">Pyr</th>
              <th style="border:none;" align="center">Ser</th>
              <th style="border:none;" align="center">Thr</th>
              <th style="border:none;" align="center">Tyr</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">SPECS</td>
              <td style="border:none;" align="left">9</td>
              <td style="border:none;" align="left">1,733</td>
              <td style="border:none;" align="left">12</td>
              <td style="border:none;" align="left">442</td>
              <td style="border:none;" align="left">44</td>
              <td style="border:none;" align="left">8</td>
              <td style="border:none;" align="left">2</td>
              <td style="border:none;" align="left">130</td>
              <td style="border:none;" align="left">5,521</td>
              <td style="border:none;" align="left">1,658</td>
              <td style="border:none;" align="left">0</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MolPort</td>
              <td style="border:none;" align="left">1,737</td>
              <td style="border:none;" align="left">23,230</td>
              <td style="border:none;" align="left">282</td>
              <td style="border:none;" align="left">18,529</td>
              <td style="border:none;" align="left">1,193</td>
              <td style="border:none;" align="left">282</td>
              <td style="border:none;" align="left">217</td>
              <td style="border:none;" align="left">5,362</td>
              <td style="border:none;" align="left">63,963</td>
              <td style="border:none;" align="left">25,301</td>
              <td style="border:none;" align="left">56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Mcule</td>
              <td style="border:none;" align="left">12,196</td>
              <td style="border:none;" align="left">106,952</td>
              <td style="border:none;" align="left">3,563</td>
              <td style="border:none;" align="left">53,700</td>
              <td style="border:none;" align="left">27,058</td>
              <td style="border:none;" align="left">3,562</td>
              <td style="border:none;" align="left">5,081</td>
              <td style="border:none;" align="left">32,100</td>
              <td style="border:none;" align="left">188,217</td>
              <td style="border:none;" align="left">100,661</td>
              <td style="border:none;" align="left">4,349</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MCE</td>
              <td style="border:none;" align="left">19</td>
              <td style="border:none;" align="left">359</td>
              <td style="border:none;" align="left">1</td>
              <td style="border:none;" align="left">133</td>
              <td style="border:none;" align="left">62</td>
              <td style="border:none;" align="left">1</td>
              <td style="border:none;" align="left">5</td>
              <td style="border:none;" align="left">296</td>
              <td style="border:none;" align="left">253</td>
              <td style="border:none;" align="left">155</td>
              <td style="border:none;" align="left">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SELLECKCHEM
(Bioactive Compound Library)</td>
              <td style="border:none;" align="left">8</td>
              <td style="border:none;" align="left">214</td>
              <td style="border:none;" align="left">2</td>
              <td style="border:none;" align="left">70</td>
              <td style="border:none;" align="left">48</td>
              <td style="border:none;" align="left">2</td>
              <td style="border:none;" align="left">2</td>
              <td style="border:none;" align="left">119</td>
              <td style="border:none;" align="left">107</td>
              <td style="border:none;" align="left">146</td>
              <td style="border:none;" align="left">1</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SELLECKCHEM (FDA approved and in clinic)</td>
              <td style="border:none;" align="left">7</td>
              <td style="border:none;" align="left">101</td>
              <td style="border:none;" align="left">1</td>
              <td style="border:none;" align="left">48</td>
              <td style="border:none;" align="left">5</td>
              <td style="border:none;" align="left">1</td>
              <td style="border:none;" align="left">2</td>
              <td style="border:none;" align="left">83</td>
              <td style="border:none;" align="left">69</td>
              <td style="border:none;" align="left">48</td>
              <td style="border:none;" align="left">0</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SELLECKCHEM (Traditional Chinese Medicine Library)</td>
              <td style="border:none;" align="left">0</td>
              <td style="border:none;" align="left">40</td>
              <td style="border:none;" align="left">0</td>
              <td style="border:none;" align="left">18</td>
              <td style="border:none;" align="left">14</td>
              <td style="border:none;" align="left">0</td>
              <td style="border:none;" align="left">1</td>
              <td style="border:none;" align="left">24</td>
              <td style="border:none;" align="left">17</td>
              <td style="border:none;" align="left">19</td>
              <td style="border:none;" align="left">0</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SELLECKCHEM
(Natural Product Library)</td>
              <td style="border:none;" align="left">0</td>
              <td style="border:none;" align="left">88</td>
              <td style="border:none;" align="left">0</td>
              <td style="border:none;" align="left">43</td>
              <td style="border:none;" align="left">44</td>
              <td style="border:none;" align="left">0</td>
              <td style="border:none;" align="left">2</td>
              <td style="border:none;" align="left">80</td>
              <td style="border:none;" align="left">57</td>
              <td style="border:none;" align="left">52</td>
              <td style="border:none;" align="left">0</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Total</td>
              <td style="border:none;" align="left">13,976</td>
              <td style="border:none;" align="left">132,717</td>
              <td style="border:none;" align="left">3,861</td>
              <td style="border:none;" align="left">72,983</td>
              <td style="border:none;" align="left">28,468</td>
              <td style="border:none;" align="left">3,856</td>
              <td style="border:none;" align="left">5,312</td>
              <td style="border:none;" align="left">38,194</td>
              <td style="border:none;" align="left">258,204</td>
              <td style="border:none;" align="left">128,040</td>
              <td style="border:none;" align="left">4,407</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </sec>
  <sec id="sec3">
    <title>SCARdock Pipeline</title>
    <p>Previously, we proposed the SCAR
strategy and developed an experimentally
verified pipeline for screening covalent inhibitors in drug screening.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> SCAR is the first strategy that screens covalent
ligands based on noncovalent docking and has been experimentally validated.<sup><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> In the SCAR strategy, the covalent residue in the protein is mutated
or removed before docking, and the distance between the bonding atoms
is used for evaluating the possibility of covalent bonding.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> To make our protocol more widely and easily
accessible, we set up the SCARdock web server for screening covalent
ligands (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A).
Users need to designate the target protein by providing a PDB ID or
uploading a PDB file directly, specify the targeting residue, and
choose a ligand data set for docking. The server performs the docking
process with AutoDock Vina v 1.1.2. As described in our previous work,<sup><xref ref-type="bibr" rid="ref24">24</xref>−<xref ref-type="bibr" rid="ref27">27</xref></sup> results are further filtered according to the docking scores, score
density, and the distances between the assumed covalent atoms. At
last, users are suggested to download the results, visually check
the docked poses, and select ligands for experimental validation accordingly.
The vendor IDs of the ligands are also provided so that users can
inquire the purchasing information from the vendors.</p>
    <fig id="fig2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Pipeline and composition
of SCARdock. (A) Pipeline of the SCARdock
server. (B) Composition of the SCARdock Web site. (C) Task submission
of SCARdock for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="4I24">4I24</ext-link> (PDB ID). (D) A comparison between a SCARdock result for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="4I24">4I24</ext-link> and the origin structure.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao2c08147_0002" id="gr2" position="float"/>
    </fig>
    <p>The backend of the SCARdock server was developed
with Django, and
the front-end was built with Vue (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B). Web site data are stored and managed
by MySQL. The visual screening pipeline of SCARdock was implemented
with Python. For receptor preparation, after a PDB file is automatically
downloaded from the PDB database or submitted directly, the specified
chain is extracted and the specified targeting residue is mutated
to Gly via PyRosetta. Then the mutated receptor is converted to a
PDBQT file by MGLTools. The molecules in the selected data set matching
the covalent residue are used in the docking progress. The default
docking parameters can be used directly, or the coordinates and sizes
of the grid box could be customized in the advanced mode. The ligands
would be discarded if the score or the score density of the first
pose is higher than the thresholds (for example: a score higher than
−8 kcal/mol, and a score density higher than −0.2 kcal/mol
per non-hydrogen atom). In addition, the distance between the bonding
atoms in the targeting residue and the compound in each docked pose
is calculated and recorded for filtering as well. The pose scores
and atom distances are saved in the result report as a reference for
manual validation. All SCARdock jobs and results are private and only
available by the user.</p>
  </sec>
  <sec id="sec4">
    <title>Utility and Discussion</title>
    <sec id="sec4.1">
      <title>Case Study: An Example
of Covalent Docking for EGFR</title>
      <p>A structure of EGFR (PDB ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="4I24">4I24</ext-link>) was used as an
example to showcase how
to screen covalent inhibitors using the SCARdock server. In the “Get
Started” page, the receptor was automatically downloaded by
providing PDB ID or uploaded with the PDB file. The chain identifier,
target residue (name and number), and ligand data sets were selected
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C). The “advanced
mode” allows users to manually set the grid box for docking
with Autodock Vina. Then the job was submitted to the server. Once
the task was done, results were checked and downloaded in the “My
results” page. In this page, the settings used in the screening
process are displayed. More details, such as parameters of the grid
box, ligand information, and docking scores, are included in the downloadable
files. In this example, SCARdock successfully retrieved the original
ligands of 4I24 from the SELLECKCHEM library with poses consistent
with the original structure, except that the remaining leaving group
increased the distortion of the docked pose (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D).</p>
    </sec>
  </sec>
  <sec id="sec5">
    <title>Results and Discussion</title>
    <p>The past decade has witnessed
a fast resurgence of the discovery
of covalent ligands. A data set of high-quality covalent ligand–protein
complexes will be of great value for the development and validation
of covalent docking tools. A manually curated data set of covalent
warheads will be of great importance for the design and optimization
of covalent ligands. A data set of covalent compounds containing experimentally
verified warheads will be highly useful for the <italic>in silico</italic> screening of covalent ligands. We provided these high-quality data
sets along with the SCARdock web server to provide help to the discovery,
design, and optimization of covalent ligands. The SCARdock server
will allow users without coding skills to screen covalent ligands
easily. In future, the covalent complex data set, the warhead data
set, and the ligand data set will keep updating.</p>
  </sec>
  <sec id="sec6">
    <title>Conclusions</title>
    <p>Based
on previous studies and PDB, a data set of covalent complex
structures and a data set of warheads were built, and all the data
were supported by the experiments in the studies. Subsequently, several
compound libraries were processed based on the warhead data set, and
the data set of compounds is ready to be applied in the SCARdock pipeline.
With the three data sets, SCARdock is accessible for users to screen
covalent ligands for their target proteins, and the details of the
ligands and warheads can be checked. In conclusion, the SCARdock web
server will be a great resource to the researchers interested in the
discovery of covalent drugs and chemical tools.</p>
  </sec>
</body>
<back>
  <notes notes-type="data-availability" id="notes2">
    <title>Data Availability Statement</title>
    <p>The SCARdock
server is freely available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.liugroup.site/scardock/">http://www.liugroup.site/scardock/</uri> or <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://scardock.com">https://scardock.com</uri>.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> The manually curated data set containing published
high-quality complex structures of covalent ligands and protein targets,
the manually collected and curated data set of experimentally confirmed
covalent warheads, and the prefiltered and ready-to-use virtual data
set of purchasable compounds are available on the SCARdock server.</p>
  </notes>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.2c08147?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.2c08147</ext-link>.<list id="silist" list-type="simple"><list-item><p>Data collection of covalent
ligand–protein complexes;
discarded general molecules such as cofactors and solutes; unique
warheads targeting 11 different residues in biological sciences papers
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.2c08147/suppl_file/ao2c08147_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao2c08147_si_001.pdf">
        <caption>
          <p>ao2c08147_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p><sup>#</sup> Sen Liu conceived
the idea and prepared the compound data sets. Qi
Song set up the web server. Lingyu Zeng prepared the covalent ligand–protein
data sets and designed the web pages. Qiang Zheng prepared the warhead
data set. Qi Song and Lingyu Zeng contributed equally.</p>
  </notes>
  <notes notes-type="COI-statement" id="notes4">
    <p>The authors
declare no competing financial interest.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>We would like to thank the support
from all the
members of our lab. This work was supported by the grants from National
Natural Science Foundation of China (31971150), Department of Science
and Technology, Hubei Provincial People’s Government (2019CFA069),
the Collaborative Grant-in-Aid of the HBUT National “111”
Center for Cellular Regulation and Molecular Pharmaceutics (XBTK-2022008),
and Hubei University of Technology.</p>
  </ack>
  <glossary id="dl1">
    <def-list>
      <title>Abbreviations</title>
      <def-item>
        <term>CADD</term>
        <def>
          <p>Computation-aided
drug discovery</p>
        </def>
      </def-item>
      <def-item>
        <term>MM</term>
        <def>
          <p>Molecular mechanism</p>
        </def>
      </def-item>
      <def-item>
        <term>MOE</term>
        <def>
          <p>Molecular Operating
Environment</p>
        </def>
      </def-item>
      <def-item>
        <term>PDB</term>
        <def>
          <p>Protein data bank</p>
        </def>
      </def-item>
      <def-item>
        <term>PROTACs</term>
        <def>
          <p>Proteolysis targeting chimeras</p>
        </def>
      </def-item>
      <def-item>
        <term>QM</term>
        <def>
          <p>Quantum mechanical</p>
        </def>
      </def-item>
      <def-item>
        <term>SCAR</term>
        <def>
          <p>Steric-clashes alleviating receptor
strategy</p>
        </def>
      </def-item>
      <def-item>
        <term>SMILES</term>
        <def>
          <p>Simplified molecular input line
entry system</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Singh</surname><given-names>J.</given-names></name>; <name><surname>Petter</surname><given-names>R. C.</given-names></name>; <name><surname>Baillie</surname><given-names>T. A.</given-names></name>; <name><surname>Whitty</surname><given-names>A.</given-names></name><article-title>The Resurgence of Covalent
Drugs</article-title>. <source>Nat. Rev. Drug Discov</source><year>2011</year>, <volume>10</volume> (<issue>4</issue>), <fpage>307</fpage>–<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3410</pub-id>.<pub-id pub-id-type="pmid">21455239</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Robertson</surname><given-names>J. G.</given-names></name><article-title>Mechanistic
Basis of Enzyme-Targeted Drugs</article-title>. <source>Biochemistry</source><year>2005</year>, <volume>44</volume> (<issue>15</issue>), <fpage>5561</fpage>–<lpage>5571</lpage>. <pub-id pub-id-type="doi">10.1021/bi050247e</pub-id>.<pub-id pub-id-type="pmid">15823014</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Sutanto</surname><given-names>F.</given-names></name>; <name><surname>Konstantinidou</surname><given-names>M.</given-names></name>; <name><surname>Dömling</surname><given-names>A.</given-names></name><article-title>Covalent Inhibitors: A Rational Approach
to Drug Discovery</article-title>. <source>RSC Medicinal Chemistry</source><year>2020</year>, <volume>11</volume> (<issue>8</issue>), <fpage>876</fpage>–<lpage>884</lpage>. <pub-id pub-id-type="doi">10.1039/D0MD00154F</pub-id>.<pub-id pub-id-type="pmid">33479682</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Gabizon</surname><given-names>R.</given-names></name>; <name><surname>Shraga</surname><given-names>A.</given-names></name>; <name><surname>Gehrtz</surname><given-names>P.</given-names></name>; <name><surname>Livnah</surname><given-names>E.</given-names></name>; <name><surname>Shorer</surname><given-names>Y.</given-names></name>; <name><surname>Gurwicz</surname><given-names>N.</given-names></name>; <name><surname>Avram</surname><given-names>L.</given-names></name>; <name><surname>Unger</surname><given-names>T.</given-names></name>; <name><surname>Aharoni</surname><given-names>H.</given-names></name>; <name><surname>Albeck</surname><given-names>S.</given-names></name>; <name><surname>Brandis</surname><given-names>A.</given-names></name>; <name><surname>Shulman</surname><given-names>Z.</given-names></name>; <name><surname>Katz</surname><given-names>B.-Z.</given-names></name>; <name><surname>Herishanu</surname><given-names>Y.</given-names></name>; <name><surname>London</surname><given-names>N.</given-names></name><article-title>Efficient Targeted Degradation via
Reversible and Irreversible Covalent PROTACs</article-title>. <source>J. Am. Chem. Soc.</source><year>2020</year>, <volume>142</volume> (<issue>27</issue>), <fpage>11734</fpage>–<lpage>11742</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b13907</pub-id>.<pub-id pub-id-type="pmid">32369353</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Xue</surname><given-names>G.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>Zhou</surname><given-names>D.</given-names></name>; <name><surname>Zuo</surname><given-names>Y.</given-names></name>; <name><surname>Fu</surname><given-names>T.</given-names></name>; <name><surname>Pan</surname><given-names>Z.</given-names></name><article-title>Protein Degradation
through Covalent Inhibitor-Based
PROTACs</article-title>. <source>Chem. Commun.</source><year>2020</year>, <volume>56</volume> (<issue>10</issue>), <fpage>1521</fpage>–<lpage>1524</lpage>. <pub-id pub-id-type="doi">10.1039/C9CC08238G</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Scott</surname><given-names>D. E.</given-names></name>; <name><surname>Bayly</surname><given-names>A. R.</given-names></name>; <name><surname>Abell</surname><given-names>C.</given-names></name>; <name><surname>Skidmore</surname><given-names>J.</given-names></name><article-title>Small Molecules, Big
Targets: Drug Discovery Faces the Protein–Protein Interaction
Challenge</article-title>. <source>Nat. Rev. Drug Discov</source><year>2016</year>, <volume>15</volume> (<issue>8</issue>), <fpage>533</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2016.29</pub-id>.<pub-id pub-id-type="pmid">27050677</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Abagyan</surname><given-names>R.</given-names></name>; <name><surname>Totrov</surname><given-names>M.</given-names></name>; <name><surname>Kuznetsov</surname><given-names>D.</given-names></name><article-title>ICM—A
New Method for Protein
Modeling and Design: Applications to Docking and Structure Prediction
from the Distorted Native Conformation</article-title>. <source>J. Comput.
Chem.</source><year>1994</year>, <volume>15</volume> (<issue>5</issue>), <fpage>488</fpage>–<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.540150503</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Jones</surname><given-names>G.</given-names></name>; <name><surname>Willett</surname><given-names>P.</given-names></name>; <name><surname>Glen</surname><given-names>R. C.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name>; <name><surname>Taylor</surname><given-names>R.</given-names></name><article-title>Development
and Validation of a Genetic Algorithm for Flexible Docking</article-title>. <source>J. Mol. Biol.</source><year>1997</year>, <volume>267</volume> (<issue>3</issue>), <fpage>727</fpage>–<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1996.0897</pub-id>.<pub-id pub-id-type="pmid">9126849</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Morris</surname><given-names>G. M.</given-names></name>; <name><surname>Huey</surname><given-names>R.</given-names></name>; <name><surname>Lindstrom</surname><given-names>W.</given-names></name>; <name><surname>Sanner</surname><given-names>M. F.</given-names></name>; <name><surname>Belew</surname><given-names>R. K.</given-names></name>; <name><surname>Goodsell</surname><given-names>D. S.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name><article-title>AutoDock4
and AutoDockTools4: Automated
Docking with Selective Receptor Flexibility</article-title>. <source>J. Comput. Chem.</source><year>2009</year>, <volume>30</volume> (<issue>16</issue>), <fpage>2785</fpage>–<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id>.<pub-id pub-id-type="pmid">19399780</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Lawandi</surname><given-names>J.</given-names></name>; <name><surname>Toumieux</surname><given-names>S.</given-names></name>; <name><surname>Seyer</surname><given-names>V.</given-names></name>; <name><surname>Campbell</surname><given-names>P.</given-names></name>; <name><surname>Thielges</surname><given-names>S.</given-names></name>; <name><surname>Juillerat-Jeanneret</surname><given-names>L.</given-names></name>; <name><surname>Moitessier</surname><given-names>N.</given-names></name><article-title>Constrained Peptidomimetics Reveal
Detailed Geometric Requirements of Covalent Prolyl Oligopeptidase
Inhibitors</article-title>. <source>J. Med. Chem.</source><year>2009</year>, <volume>52</volume> (<issue>21</issue>), <fpage>6672</fpage>–<lpage>6684</lpage>. <pub-id pub-id-type="doi">10.1021/jm901013a</pub-id>.<pub-id pub-id-type="pmid">19888757</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Labarre</surname><given-names>A.</given-names></name>; <name><surname>Stille</surname><given-names>J. K.</given-names></name>; <name><surname>Patrascu</surname><given-names>M. B.</given-names></name>; <name><surname>Martins</surname><given-names>A.</given-names></name>; <name><surname>Pottel</surname><given-names>J.</given-names></name>; <name><surname>Moitessier</surname><given-names>N.</given-names></name><article-title>Docking Ligands
into Flexible and Solvated Macromolecules.
8. Forming New Bonds – Challenges and Opportunities</article-title>. <source>J. Chem. Inf. Model.</source><year>2022</year>, <volume>62</volume>, <fpage>1061</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c00701</pub-id>.<pub-id pub-id-type="pmid">35133156</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Ouyang</surname><given-names>X.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name>; <name><surname>Su</surname><given-names>C. T. T.</given-names></name>; <name><surname>Ge</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Kwoh</surname><given-names>C. K.</given-names></name><article-title>CovalentDock: Automated Covalent Docking with Parameterized
Covalent Linkage Energy Estimation and Molecular Geometry Constraints</article-title>. <source>J. Comput. Chem.</source><year>2013</year>, <volume>34</volume> (<issue>4</issue>), <fpage>326</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.23136</pub-id>.<pub-id pub-id-type="pmid">23034731</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Zhu</surname><given-names>K.</given-names></name>; <name><surname>Borrelli</surname><given-names>K. W.</given-names></name>; <name><surname>Greenwood</surname><given-names>J. R.</given-names></name>; <name><surname>Day</surname><given-names>T.</given-names></name>; <name><surname>Abel</surname><given-names>R.</given-names></name>; <name><surname>Farid</surname><given-names>R. S.</given-names></name>; <name><surname>Harder</surname><given-names>E.</given-names></name><article-title>Docking Covalent Inhibitors:
A Parameter
Free Approach to Pose Prediction and Scoring</article-title>. <source>J. Chem. Inf. Model.</source><year>2014</year>, <volume>54</volume> (<issue>7</issue>), <fpage>1932</fpage>–<lpage>1940</lpage>. <pub-id pub-id-type="doi">10.1021/ci500118s</pub-id>.<pub-id pub-id-type="pmid">24916536</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Toledo
Warshaviak</surname><given-names>D.</given-names></name>; <name><surname>Golan</surname><given-names>G.</given-names></name>; <name><surname>Borrelli</surname><given-names>K. W.</given-names></name>; <name><surname>Zhu</surname><given-names>K.</given-names></name>; <name><surname>Kalid</surname><given-names>O.</given-names></name><article-title>Structure-Based Virtual Screening Approach for Discovery of Covalently
Bound Ligands</article-title>. <source>J. Chem. Inf. Model.</source><year>2014</year>, <volume>54</volume> (<issue>7</issue>), <fpage>1941</fpage>–<lpage>1950</lpage>. <pub-id pub-id-type="doi">10.1021/ci500175r</pub-id>.<pub-id pub-id-type="pmid">24932913</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>London</surname><given-names>N.</given-names></name>; <name><surname>Miller</surname><given-names>R. M.</given-names></name>; <name><surname>Krishnan</surname><given-names>S.</given-names></name>; <name><surname>Uchida</surname><given-names>K.</given-names></name>; <name><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name><surname>Eidam</surname><given-names>O.</given-names></name>; <name><surname>Gibold</surname><given-names>L.</given-names></name>; <name><surname>Cimermančič</surname><given-names>P.</given-names></name>; <name><surname>Bonnet</surname><given-names>R.</given-names></name>; <name><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name><surname>Taunton</surname><given-names>J.</given-names></name><article-title>Covalent Docking of
Large Libraries for the Discovery of Chemical Probes</article-title>. <source>Nat. Chem. Biol.</source><year>2014</year>, <volume>10</volume> (<issue>12</issue>), <fpage>1066</fpage>–<lpage>1072</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.1666</pub-id>.<pub-id pub-id-type="pmid">25344815</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Scholz</surname><given-names>C.</given-names></name>; <name><surname>Knorr</surname><given-names>S.</given-names></name>; <name><surname>Hamacher</surname><given-names>K.</given-names></name>; <name><surname>Schmidt</surname><given-names>B.</given-names></name><article-title>DOCKTITE—a Highly
Versatile Step-by-Step Workflow for Covalent Docking and Virtual Screening
in the Molecular Operating Environment</article-title>. <source>J. Chem.
Inf. Model.</source><year>2015</year>, <volume>55</volume> (<issue>2</issue>), <fpage>398</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1021/ci500681r</pub-id>.<pub-id pub-id-type="pmid">25541749</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Hoffer</surname><given-names>L.</given-names></name>; <name><surname>Saez-Ayala</surname><given-names>M.</given-names></name>; <name><surname>Horvath</surname><given-names>D.</given-names></name>; <name><surname>Varnek</surname><given-names>A.</given-names></name>; <name><surname>Morelli</surname><given-names>X.</given-names></name>; <name><surname>Roche</surname><given-names>P.</given-names></name><article-title>CovaDOTS: <italic>In Silico</italic> Chemistry-Driven Tool to Design
Covalent Inhibitors Using a Linking Strategy</article-title>. <source>J. Chem. Inf. Model.</source><year>2019</year>, <volume>59</volume> (<issue>4</issue>), <fpage>1472</fpage>–<lpage>1485</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00960</pub-id>.<pub-id pub-id-type="pmid">30908019</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Wei</surname><given-names>L.</given-names></name>; <name><surname>Wen</surname><given-names>W.</given-names></name>; <name><surname>Rao</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Lei</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>K.</given-names></name>; <name><surname>Hu</surname><given-names>S.</given-names></name>; <name><surname>Song</surname><given-names>R.</given-names></name>; <name><surname>Ren</surname><given-names>Y.</given-names></name>; <name><surname>Wan</surname><given-names>J.</given-names></name><article-title>Cov_FB3D: A de Novo
Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and
Machine-Learning-Based Synthetic Tractability Evaluation</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>9</issue>), <fpage>4388</fpage>–<lpage>4402</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b01197</pub-id>.<pub-id pub-id-type="pmid">32233478</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Scarpino</surname><given-names>A.</given-names></name>; <name><surname>Petri</surname><given-names>L.</given-names></name>; <name><surname>Knez</surname><given-names>D.</given-names></name>; <name><surname>Imre</surname><given-names>T.</given-names></name>; <name><surname>Ábrányi-Balogh</surname><given-names>P.</given-names></name>; <name><surname>Ferenczy</surname><given-names>G. G.</given-names></name>; <name><surname>Gobec</surname><given-names>S.</given-names></name>; <name><surname>Keserű</surname><given-names>G. M.</given-names></name><article-title>WIDOCK:
A Reactive Docking Protocol for Virtual Screening of Covalent Inhibitors</article-title>. <source>J. Comput. Aided Mol. Des</source><year>2021</year>, <volume>35</volume> (<issue>2</issue>), <fpage>223</fpage>–<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-020-00371-5</pub-id>.<pub-id pub-id-type="pmid">33458809</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Wu</surname><given-names>Q.</given-names></name>; <name><surname>Huang</surname><given-names>S.-Y.</given-names></name><article-title>HCovDock: An Efficient
Docking Method for Modeling
Covalent Protein–Ligand Interactions</article-title>. <source>Briefings in Bioinformatics</source><year>2023</year>, <volume>24</volume> (<issue>1</issue>), <fpage>bbac559</fpage><pub-id pub-id-type="doi">10.1093/bib/bbac559</pub-id>.<pub-id pub-id-type="pmid">36573474</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Wei</surname><given-names>L.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Rao</surname><given-names>L.</given-names></name>; <name><surname>Ren</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name>; <name><surname>Wan</surname><given-names>J.</given-names></name><article-title>Cov_DOX: A Method for Structure Prediction of Covalent
Protein–Ligand Bindings</article-title>. <source>J. Med. Chem.</source><year>2022</year>, <volume>65</volume> (<issue>7</issue>), <fpage>5528</fpage>–<lpage>5538</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02007</pub-id>.<pub-id pub-id-type="pmid">35353519</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Ouyang</surname><given-names>X.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name>; <name><surname>Ge</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>R.</given-names></name>; <name><surname>Kwoh</surname><given-names>C. K.</given-names></name><article-title>CovalentDock
Cloud: A Web Server for Automated Covalent Docking</article-title>. <source>Nucleic Acids Res.</source><year>2013</year>, <volume>41</volume> (<issue>W1</issue>), <fpage>W329</fpage>–<lpage>W332</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt406</pub-id>.<pub-id pub-id-type="pmid">23677616</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="weblink" id="cit23"><source>Dockovalent - A Free Covalent Docking Server</source>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://covalent.docking.org">http://covalent.docking.org</uri> (accessed 2022–03–25).</mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name><article-title>Potential Clinical
Drugs as Covalent Inhibitors of the Priming Proteases of the Spike
Protein of SARS-CoV-2</article-title>. <source>Computational and Structural
Biotechnology Journal</source><year>2020</year>, <volume>18</volume>, <fpage>2200</fpage>–<lpage>2208</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2020.08.016</pub-id>.<pub-id pub-id-type="pmid">32868983</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name><article-title>Potential Covalent Drugs Targeting
the Main Protease of the SARS-CoV-2 Coronavirus</article-title>. <source>Bioinformatics</source><year>2020</year>, <volume>36</volume> (<issue>11</issue>), <fpage>3295</fpage>–<lpage>3298</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btaa224</pub-id>.<pub-id pub-id-type="pmid">32239142</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>Q.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name><article-title>Repurposing Clinical
Drugs as AdoMetDC Inhibitors Using the SCAR Strategy</article-title>. <source>Front. Pharmacol.</source><year>2020</year>, <volume>11</volume>, <fpage>248</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00248</pub-id>.<pub-id pub-id-type="pmid">32218733</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Ai</surname><given-names>Y.</given-names></name>; <name><surname>Yu</surname><given-names>L.</given-names></name>; <name><surname>Tan</surname><given-names>X.</given-names></name>; <name><surname>Chai</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name><article-title>Discovery of Covalent
Ligands via Noncovalent Docking by Dissecting Covalent Docking Based
on a “Steric-Clashes Alleviating Receptor (SCAR)” Strategy</article-title>. <source>J. Chem. Inf. Model.</source><year>2016</year>, <volume>56</volume> (<issue>8</issue>), <fpage>1563</fpage>–<lpage>1575</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00334</pub-id>.<pub-id pub-id-type="pmid">27411028</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Du</surname><given-names>H.</given-names></name>; <name><surname>Gao</surname><given-names>J.</given-names></name>; <name><surname>Weng</surname><given-names>G.</given-names></name>; <name><surname>Ding</surname><given-names>J.</given-names></name>; <name><surname>Chai</surname><given-names>X.</given-names></name>; <name><surname>Pang</surname><given-names>J.</given-names></name>; <name><surname>Kang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>D.</given-names></name>; <name><surname>Cao</surname><given-names>D.</given-names></name>; <name><surname>Hou</surname><given-names>T.</given-names></name><article-title>CovalentInDB:
A Comprehensive Database Facilitating the Discovery of Covalent Inhibitors</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>, <volume>49</volume> (<issue>D1</issue>), <fpage>D1122</fpage>–<lpage>D1129</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa876</pub-id>.<pub-id pub-id-type="pmid">33068433</pub-id></mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>DeLano</surname><given-names>W. L.</given-names></name><article-title>Pymol:
An Open-Source Molecular Graphics Tool</article-title>. <source>CCP4
Newsletter on protein crystallography</source><year>2002</year>, <volume>40</volume> (<issue>1</issue>), <fpage>82</fpage>–<lpage>92</lpage>.</mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="weblink" id="cit30"><source>RCSB PDB</source>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org">https://www.rcsb.org</uri> (accessed 2022–03–25).</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="undeclared" id="cit31"><person-group person-group-type="allauthors"><name><surname>Landrum</surname><given-names>G.</given-names></name></person-group><source>RDKit: Open-Source Cheminformatics</source>; <year>2016</year>.</mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Trott</surname><given-names>O.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name><article-title>AutoDock Vina: Improving
the Speed and Accuracy of
Docking with a New Scoring Function, Efficient Optimization, and Multithreading</article-title>. <source>J. Comput. Chem.</source><year>2010</year>, <volume>31</volume> (<issue>2</issue>), <fpage>455</fpage>–<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id>.<pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Sotriffer</surname><given-names>C.</given-names></name><article-title>Docking of
Covalent Ligands: Challenges and Approaches</article-title>. <source>Mol. Inf.</source><year>2018</year>, <volume>37</volume> (<issue>9–10</issue>), <elocation-id>1800062</elocation-id><pub-id pub-id-type="doi">10.1002/minf.201800062</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Bianco</surname><given-names>G.</given-names></name>; <name><surname>Goodsell</surname><given-names>D. S.</given-names></name>; <name><surname>Forli</surname><given-names>S.</given-names></name><article-title>Selective and Effective: Current
Progress in Computational Structure-Based Drug Discovery of Targeted
Covalent Inhibitors</article-title>. <source>Trends Pharmacol. Sci.</source><year>2020</year>, <volume>41</volume> (<issue>12</issue>), <fpage>1038</fpage>–<lpage>1049</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2020.10.005</pub-id>.<pub-id pub-id-type="pmid">33153778</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="weblink" id="cit35"><source>SCARdock</source>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.liugroup.site/scardock">http://www.liugroup.site/scardock</uri> (accessed 2022–03–25).</mixed-citation>
    </ref>
  </ref-list>
</back>
